Atlas Trials

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Clinical trial NCT02454842 · TERMINATED

Trial details

NCT number
NCT02454842
Sponsor
Rain Oncology Inc
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung CancerNSCLCNon-squamous NSCLC
Start date
2015-06-01
Primary completion
2017-01-01
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.